14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:OPXA
Delisted

Opexa Therapeutics Fund Signals

$0.97
+0 (+0%)
At Close: Jan 16, 2018

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 70 days ( -13.12 % )
Last Price $0.97 0 %
High/ Low $0.97 - $0.97 0%
Chg 7 Days N/A $0.97 $0.97
Chg 30 Days N/A $0.97 $0.97
Chg 12 mos 1.04 % $0.96 $0.97
Trend - 3 mos N/A Width: 0 %
Trend - 12 mos 11.47 % Width: 92.39 %
Pred. range - 3 mos $0.97 - $0.97 0 % - 0 %
Pred. range - 12 mos $0.714 - $1.37 -26.41 % - 41.58 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Buy Dec 11, 2017 - 24 days
Short/Long MA avg 3 mos Buy Dec 11, 2017 - 24 days
Short MA avg 12 mos Sell Dec 01, 2017 - 30 days
Long MA avg 12 mos Sell Nov 30, -1 - N/A days
Short/Long MA avg 12 mos Sell Nov 30, -1 - N/A days
Pivot Short Buy Jan 12, 2018 - 3 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Opexa Therapeutics

Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases based on its proprietary T-cell technology. The company’s lead product candidate is Tcelna, a novel T-cell immunotherapy, which is in Phase IIb clinical development for the treatment of patients with secondary progressive MS. It is also developing OPX-212 as an autologous T-cell immunotherapy t... OPXA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT